Dear Colleagues:
Welcome to the June issue of Innovations in Clinical Neuroscience. In this month’s, “The Interface,” Sansone and Sansone examine the use of three currently available serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine, milnacipran) for pharmacological treatment of obsessive compulsive disorder.
Next, Spiegel and Lim review Korsakoff’s syndrome, an amnestic disorder associated with long-standing alcohol misuse that involves both anterograde and retrograde amnesia. Using a case report as an example, the authors discuss similarities (and differences) with medial temporal lobe memory disorders and the role of frontal lobe dysfunction in its retrograde amnesia.
Following this, Quiroz et al present data on local injection-site tolerability and safety of risperidone long-acting injectable and comparability of systemic exposure of deltoid versus gluteal injections. The authors found that the overall safety and tolerability profile of risperidone long-acting injectable was comparable when administered as an intramuscular injection in the deltoid and gluteal sites.
Next, Mariano et al review the challenges that co-diagnosis of a major mental illness and antisocial personality disorder in an individual can present to the treatment team and to the community as a whole, including administrative, clinical, legal, and ethical issues. Based on an actual case, the authors discuss how clinicians could fulfill the obligation to the patient, mental health system, judicial system, and the community under these circumstances.
Following this, Sansone, Lam, and Weiderman present data on mental healthcare utilization in relationship to a history of criminal behavior in a sample of internal medicine outpatients. Using both a sample and methodology that is unique to the current literature, the authors found relationships between past mental health treatment and history of criminal behavior.
Next, in this month’s “Research to Practice” column, Targum interviews Andrew A. Nierenberg, Professor of Psychiatry at the Harvard Medical School and Director of the Bipolar Clinic and Research Program at the Massachusetts General Hospital, regarding the diagnostic issue of “mixed” depression. Dr. Nierenberg gives his take on specific manic-type symptoms as well as implicit treatment dilemmas.
And finally, we wrap the issue up with an installment of “Risk Management.” This month, Denita Neal, JD, from PRMS Inc. answers a reader’s question regarding liability considerations when investing in an electronic records system.
Sincerely,
Amir Kalali, MD
Editor, Innovations in Clinical Neuroscience
